With the overall stock market very overbought, the four highest-yielding Dogs of the Dow look like outstanding ideas now.

A trusted partner to 19 of the top 20 pharmaceutical companies, Medidata continues to break ground with new categories of critical patient-centric experiences, seamlessly integrating AI into its suite ...

We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal ...